Free Trial

Ultragenyx Pharmaceutical (RARE) Competitors

Ultragenyx Pharmaceutical logo
$28.40 -1.07 (-3.63%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$29.04 +0.64 (+2.25%)
As of 09/23/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RARE vs. QGEN, BBIO, ROIV, MRNA, ELAN, VRNA, RVMD, GRFS, ABVX, and RYTM

Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Grifols (GRFS), Abivax (ABVX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

Ultragenyx Pharmaceutical vs. Its Competitors

QIAGEN (NYSE:QGEN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

QIAGEN currently has a consensus target price of $49.69, suggesting a potential upside of 8.95%. Ultragenyx Pharmaceutical has a consensus target price of $81.50, suggesting a potential upside of 186.97%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than QIAGEN.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
QIAGEN
0 Sell rating(s)
8 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.27
Ultragenyx Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.92

QIAGEN has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.

In the previous week, QIAGEN and QIAGEN both had 7 articles in the media. Ultragenyx Pharmaceutical's average media sentiment score of 0.99 beat QIAGEN's score of 0.91 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
QIAGEN
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ultragenyx Pharmaceutical
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

QIAGEN has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.98B5.12$83.59M$1.6926.98
Ultragenyx Pharmaceutical$560.23M4.89-$569.18M-$5.53-5.14

70.0% of QIAGEN shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

QIAGEN has a net margin of 18.30% compared to Ultragenyx Pharmaceutical's net margin of -87.34%. QIAGEN's return on equity of 14.77% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
QIAGEN18.30% 14.77% 8.87%
Ultragenyx Pharmaceutical -87.34%-237.48%-37.66%

Summary

QIAGEN beats Ultragenyx Pharmaceutical on 10 of the 15 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RARE vs. The Competition

MetricUltragenyx PharmaceuticalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.84B$3.16B$5.76B$10.51B
Dividend YieldN/A2.36%5.53%4.57%
P/E Ratio-5.1421.0476.4326.62
Price / Sales4.89252.12473.3192.90
Price / CashN/A46.3537.4661.85
Price / Book10.299.7813.616.45
Net Income-$569.18M-$52.73M$3.29B$271.57M
7 Day Performance-1.08%3.16%1.87%2.61%
1 Month Performance-4.63%4.69%4.03%7.28%
1 Year Performance-50.59%16.37%77.41%29.60%

Ultragenyx Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RARE
Ultragenyx Pharmaceutical
4.3883 of 5 stars
$28.40
-3.6%
$81.50
+187.0%
-50.7%$2.84B$560.23M-5.141,294Positive News
QGEN
QIAGEN
4.3622 of 5 stars
$45.39
+0.2%
$49.69
+9.5%
+5.5%$10.09B$1.98B26.825,765
BBIO
BridgeBio Pharma
4.4951 of 5 stars
$51.47
+0.5%
$63.94
+24.2%
+102.8%$9.84B$221.90M-12.58400
ROIV
Roivant Sciences
3.4223 of 5 stars
$13.95
-0.9%
$17.67
+26.6%
+23.9%$9.53B$29.05M-19.93860Trending News
Insider Trade
Analyst Revision
MRNA
Moderna
4.4574 of 5 stars
$23.88
+1.6%
$41.81
+75.1%
-59.8%$9.29B$3.24B-3.175,800Trending News
ELAN
Elanco Animal Health
2.5844 of 5 stars
$18.63
+0.5%
$17.33
-6.9%
+28.5%$9.25B$4.44B21.669,000Positive News
VRNA
Verona Pharma PLC American Depositary Share
2.0305 of 5 stars
$106.37
-0.1%
$109.00
+2.5%
+259.0%$9.17B$42.28M-107.4430Positive News
RVMD
Revolution Medicines
4.2884 of 5 stars
$46.20
-0.8%
$73.67
+59.5%
+3.7%$8.64B$11.58M-10.27250
GRFS
Grifols
3.9122 of 5 stars
$9.63
-2.5%
$10.30
+7.0%
+11.9%$6.62B$7.45B8.2323,822Positive News
ABVX
Abivax
2.7984 of 5 stars
$85.87
+2.2%
$99.43
+15.8%
+655.2%$6.49BN/A0.0061
RYTM
Rhythm Pharmaceuticals
3.2028 of 5 stars
$96.03
-0.2%
$101.57
+5.8%
+93.3%$6.38B$130.13M-31.90140Positive News

Related Companies and Tools


This page (NASDAQ:RARE) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners